Research in the Lynch Lab focuses primarily on the human microbiota in both respiratory and gastrointestinal tracts, environmental microbial exposures that shape its development and its role in chronic inflammatory diseases.

Disease Origins

• Leverage the gut microbiome to predict disease risk
• Identify early-life pathogenic community states and the underlying mechanisms of disease genesis

 

Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation

Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosh D, Panzer AR, LaMere B, Rackaityte E, Lukacs NW, Wegienka G, Boushey HA, Ownby DR, Zoratti EM, Levin AM, Johnson CC, Lynch SV. Nature Medicine, 2016.

 

 

 

Viable bacterial colonization is highly limited in the human intestine in utero

Rackaityte E, Halkias J, Fukui EM, Mendoza VF, Hayzelden C, Crawford ED, Fujimura KE, Burt TD, Lynch SV. Nature Medicine, 2020.

 

 

Established Disease

• Leverage gut microbiome data to explain clinical and immunological outcomes within specific chronic inflammatory disease indications
• Identify networks of pathogens and their mechanisms of immune activation
• Determine relationships between the gut microbiome and treatment

 

Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma

McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M, Teach SJ, Togias A, Boushey HA, Gern JE, Jackson DJ, Lynch SV; National Institute of Allergy and Infectious Diseases–sponsored Inner-City Asthma Consortium. J Allergy Clin Immunol., 2019.

 

 

 

Community ecology as a framework for human microbiome research

Gilbert JA, Lynch SV. Nature Medicine, 2019.

 

Therapeutic Development

• Develop rationally designed probiotic and synbiotic cocktails for induction of immune tolerance

 

Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance

Levan SR, Stamnes KA, Lin DL, Panzer AR, Fukui E, McCauley K, Fujimura KE, McKean M, Ownby DR, Zoratti EM, Boushey HA, Cabana MD, Johnson CC, Lynch SV. Nature Microbiology, 2019.

 

 

 

Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by Lactobacillus supplementation

Durack J, Kimes NE, Lin DL, Rauch M, McKean M, McCauley K, Panzer AR, Mar JS, Cabana MD, Lynch SV. Nature Communications, 2018.